Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers

Bayer

Status and phase

Completed

Phase 1

Conditions

Diagnostic Imaging

Treatments

Drug: F-18 DPA-714 (BAY85-8102)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01009359

13150

2009-009358-26 (EudraCT Number)

Details and patient eligibility

About

PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.

Enrollment

22 patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Able to give fully informed consent in writing
Males or females aged >/= 50 years
No significant disease or drug use
Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging:
Patient and designee capable of giving fully informed consent in writing
Patient fulfils DSM-IV and NINCDS-ADRA criteria for probable Alzheimers disease
Patient has undergone physical and neurological examination, ECG and test of routine hematological and biochemical parameters prior to radiotracer administration Exclusion Criteria:- Pregnancy or lactation
Current unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)